Physician profile
Robert E Gomara
NPI 1831156066
$3,692.95
in general payments reported to CMS, 2019-2025
28 companies · $750 in 2025
The $750 reported for 2025 was more than what 79% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $318 · 2021: $390 · 2022: $474 · 2023: $586 · 2024: $809 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,144.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $631.58 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $509.83 | 2022-2025 | |
| Abbvie INC. | $392.94 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $389.89 | 2023-2025 | Bylvay |
| Janssen Scientific Affairs, LLC | $261.11 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $236.09 | 2021-2025 | Eohilia, Gattex |
| Nestle Healthcare Nutrition INC. | $194.39 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $153.57 | 2022-2025 | Dupixent |
| Medtronic, INC. | $150.48 | 2022 | |
| Qol Medical, LLC | $145.01 | 2019-2025 | Sucraid, Sucraid |
| Mirum Pharmaceuticals, INC. | $97.92 | 2023-2024 | Livmarli |
| Amgen INC. | $85.81 | 2020-2024 | Tepezza |
| Phadia US INC. | $65.38 | 2019-2023 | Immunocap |
| Alexion Pharmaceuticals, INC. | $57.34 | 2019 | |
| Travere Therapeutics, INC. | $48.00 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $29.03 | 2021 | |
| Intrabio INC | $26.83 | 2025 | Aqneursa |
| Eton Pharmaceuticals, INC. | $24.17 | 2025 | Nitisinone, Galzin, Carglumic Acid |
| Mauna Kea Technologies, INC. | $23.46 | 2025 | |
| Albireo Pharma, INC. | $23.09 | 2023 | Bylvay |
| Orphalan INC | $21.87 | 2024 | Cuvrior |
| Celltrion USA INC. | $21.00 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $20.25 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.29 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $19.26 | 2024 | |
| Amryt Pharma Holdings Ltd | $17.73 | 2021 | |
| Aytu Biopharma, INC. | $13.94 | 2020 | |
| Olympus America INC. | $13.69 | 2025 | Endoclot Phs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gomara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.